Drug Industry Antitrust Act. hearings before the United States Senate Committee on the Judiciary, Subcommittee on Antitrust and Monopoly, Eighty-Seventh Congress, first session, on July 5, 6, 18-21, 25, 1961. Part 1, A.M.A. and Medical Authorities :
Considers S. 1552 and companion H.R. 6245, the Drug Industry Antitrust Act, to amend the Federal Food, Drug, and Cosmetic Act and Sherman Antitrust Act to establish drug company licensing procedures, to require FDA to certify the effectiveness of all new drugs, to require advertisements sent to phys...
| Corporate Authors: | , |
|---|---|
| Format: | Government Document eBook |
| Language: | English |
| Published: |
Washington :
U.S. G.P.O.,
1961.
|
| Series: | U.S. Congressional Hearings.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
| Summary: | Considers S. 1552 and companion H.R. 6245, the Drug Industry Antitrust Act, to amend the Federal Food, Drug, and Cosmetic Act and Sherman Antitrust Act to establish drug company licensing procedures, to require FDA to certify the effectiveness of all new drugs, to require advertisements sent to physicians to contain FDA warnings on the drug, and to limit drug company rights to exclusive production of patented drugs. Considers (87) S. 1552, (87) H.R. 6245. |
|---|---|
| Item Description: | Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection. Reuse except for individual research requires license from ProQuest, LLC. Electronic resource. |
| Physical Description: | 1 online resource. |
| Format: | System requirements: PDF reader software. |